DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes

Oncologist

Volumn 18, Issue 10, 2013, Pages 1063-1073

  Santarpia, Libero ^a   Iwamoto, Takayuki ^b   Leo, Angelo Di ^a   Hayashi, Naoki ^c   Bottai, Giulia ^a   Stampfer, Martha ^d   André, Fabrice ^e   Turner, Nicholas C ^f   Fraser Symmans, W ^g   Hortobágyi, Gabriel N ^g   Pusztai, Lajos ^h   Bianchini, Giampaolo ⁱ  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e INSERM   (France)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF TEXAS   (United States)

^h YALE CANCER CENTER   (United States)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Breast cancer subtypes; DNA damaging agents; DNA repair pathways; Neoadjuvant therapies; Predictive factors

Indexed keywords

ANTHRACYCLINE; ATM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MISMATCH REPAIR PROTEIN PMS2; PROGESTERONE RECEPTOR; PROTEIN MSH2; PROTEIN MSH6; TAXANE DERIVATIVE; RECQ HELICASE; RECQL4 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DNA REPAIR; GENE EXPRESSION PROFILING; GENE SILENCING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION PROCESS; ADULT; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HOMOLOGOUS RECOMBINATION; PATHOLOGY; PROGNOSIS;

ADULT; BREAST NEOPLASMS; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOLOGOUS RECOMBINATION; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; RECQ HELICASES; TRANSCRIPTOME;

EID: 84886075912     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0163     Document Type: Article

References (50)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. NEngl JMed2009;360:790-800.
2. Gatza ML, Lucas JE, Barry WT et al. A pathwaybased classification of human breast cancer. Proc Natl Acad Sci U S A 2010;107:6994-6999.
3. Santarpia L, Qi Y, Stemke-Hale K et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012;134:333-343.
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
5. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486: 405-409.
6. van 't Veer LJ, Dai H, van de VijverMJet al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
7. Iwamoto T, Bianchini G, Booser D et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011;103:264-272.
8. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 2012;30:1996-2004.
9. Foster SS, De S, Johnson LK et al. Cell cycle-and DNArepair pathway-specific effects of apoptosison tumor suppression. Proc Natl Acad Sci U S A 2012; 109:9953-9958.
10. Badura M, Braunstein S, Zavadil J et al. DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proc Natl Acad Sci U S A 2012;109:18767-18772.
11. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-1078.
12. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12:587-598.
13. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
14. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-17084.
15. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10: 515-527.
16. Bianchini G, Qi Y, Alvarez RH et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and-negative cancers. J Clin Oncol 2010;28:4316-4323.
17. Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010;28:4111-4119.
18. Bianchini G, Iwamoto T, Qi Y et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010;70:8852-8862.
19. Wang J, Wen S, Symmans WF et al. The bimodality index: A criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 2009;7:199-216.
20. Vaz-Luis I, Winer EP, Lin NU. Humanepidermal growth factor receptor-2-positive breast cancer: Does estrogen receptor status define two distinct subtypes? Ann Oncol 2013;24:283-291.
21. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272.
22. Zhang J, Willers H, Feng Z et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708-718.
23. Pusztai L, AyersM, Stec Jet al. Geneexpression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogenpositive tumors. Clin Cancer Res 2003;9:2406-2415.
24. Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-451.
25. Dent R, Trudeau M, Pritchard KI et al. Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434.
26. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
27. Desmedt C, Ruíz-García E, André F. Gene expression predictors in breast cancer: Current status, limitations and perspectives. Eur J Cancer 2008;44: 2714-2720.
28. Prat A, Cheang MC, MartínMet al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 2013;31:203-209.
29. Nitiss JL. DNAtopoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009;9:327-337.
30. Sparano JA, Goldstein LJ, Davidson NE et al. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2012;134:751-757.
31. Perreard L, Fan C, Quackenbush JF et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006;8:R23.
32. Naryzhny SN. Proliferating cell nuclear antigen: A proteomics view. Cell Mol Life Sci 2008;65: 3789-3808.
33. Yousefzadeh MJ, Wood RD. DNA polymerase POLQ and cellular defense against DNA damage. DNA Repair (Amst) 2013;12:1-9.
34. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-10398.
35. Lemée F, Bergoglio V, Fernandez-Vidal A et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A 2010;107:13390-13395.
36. Li Z, Xiao W, McCormick JJ et al. Identification of a protein essential for a major pathway used by human cells to avoid UV-induced DNA damage. Proc Natl Acad Sci U S A 2002;99:4459-4464.
37. Ye C, Cai Q, Dai Q et al. Expression patterns of theATMgene in mammary tissues and their associations with breast cancer survival. Cancer 2007; 109:1729-1735.
38. Di Leo A, Desmedt C, Bartlett JM et al. HER2/ TOP2A Meta-analysis Study Group. HER2 and TOP2Aas predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatmentof breast cancer:Ameta-analysis of individual patient data Lancet Oncol 2011;12:1134-1142.
39. Arriola E, Marchio C, Tan DS et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88: 491-503.
40. PressMF, Sauter G, BuyseMet al. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011;29: 859-867.
41. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-1506.
42. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
43. Burstein HJ, Piccart-GebhartMJ, Perez EA et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: Should we abandon anthracyclines? J Clin Oncol 2012;30:2179-2182.
44. Luo Y, Lin FT, Lin WC. ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage. Mol Cell Biol 2004;24:6430-6444.
45. KennedyRD, QuinnJE, MullanPBet al. Therole of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668.
46. von Minckwitz G, MartinM, WilsonGet al. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit Rev Oncol Hematol 2013;85:315-331.
47. Petkovic M, Dietschy T, Freire R et al. The human Rothmund-Thomson syndrome gene product, RECQL4, localizes to distinct nuclear foci that coincide with proteins involved in the maintenance of genome stability J Cell Sci 2005;118:4261-4269.
48. Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: Do we need more evidence? Breast Cancer Res 2012;14:115.
49. Tutt A, Robson M, Garber JE et al. Oral poly-(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer:Aproof-of-concept trial. Lancet 2010;376:235-244.
50. Aziz K, NowsheenS, PanteliasGet al. Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy. Pharmacol Ther 2012;133:334-350.